AB Soft ii manual Cancer Epidemiology

metastases in cancer patients]. Nippon Igaku Hoshasen Gakkai Zasshi 65(4): 399-410, 10/2005.

24.Pistevou-Gompaki K, Kouloulias VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, Gompakis N, Kouvaris J. Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life. Curr Med Res Opin 20(2): 159-163, 2004.

25.Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 4(1): 31-37, 6/2005.

26.Tester W, Ackler J, Tijani L, Leighton J. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma. Cancer J 12(4): 299- 304, 7/2006.

27.Thanos L, Mylona S, Galani P, Tzavoulis D, Kalioras V, Tanteles S, Pomoni M. Radiofrequency ablation of osseous metastases for the palliation of pain. Skeletal Radiol 37(3): 189-194, 3/2008.

28.Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 67(1): 264-272, 1/2007.

29.Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10): 1869-1876, 5/2005.

30.Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17(6): 986-989, 6/2006.

31.Wu JS, Monk G, Clark T, Robinson J, Eigl BJ, Hagen N. Palliative radiotherapy improves pain and reduces functional

interference in patients with painful bone metastases: a

quality assurance study. Clin Oncol (R Coll Radiol ) 18(7): 539- 544, 9/2006.

32.Yamada K, Kohno N. [Efficacy of bisphosphonates for bone pain control]. Nippon Rinsho 65(1): 152-156, 1/2007.

Cancer Epidemiology

1.Beck SL, Falkson G. Prevalence and management of cancer pain in South Africa. Pain 94(1): 75-84, 10/2001.

2.Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330(9): 592-596, 3/1994.

3.Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med 127(9): 813-816, 11/1997.

4.Costantini M, Viterbori P, Flego G. Prevalence of pain in Italian hospitals: results of a regional cross-sectional survey. J Pain Symptom Manage 23(3): 221-230, 3/2002.

5.Crosby FE, Colestro J, Ventura MR, Graham K. Survey of pain among veterans in western New York. Pain Manag Nurs 7(1): 12-22, 3/2006.

6.Enting RH, Oldenmenger WH, Van Gool AR, van der Rijt CC, Sillevis Smitt PA. The effects of analgesic prescription and patient adherence on pain in a Dutch outpatient cancer population. J Pain Symptom Manage 34(5): 523-531, 11/2007.

7.Everdingen MHJV, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 132(3): 312-320, 12/2007.

8.Garbez RO, Chan GK, Neighbor M, Puntillo K. Pain after discharge: a pilot study of factors associated with pain management and functional status. Journal of Emergency Nursing 32(4): 288-293, 8/2006.

19 20